279 related articles for article (PubMed ID: 21715364)
1. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Ueno H; Okusaka T; Furuse J; Yamao K; Funakoshi A; Boku N; Ohkawa S; Yokosuka O; Tanaka K; Moriyasu F; Nakamori S; Sato T
Jpn J Clin Oncol; 2011 Aug; 41(8):953-8. PubMed ID: 21715364
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Oh DY; Cha Y; Choi IS; Yoon SY; Choi IK; Kim JH; Oh SC; Kim CD; Kim JS; Bang YJ; Kim YH
Cancer Chemother Pharmacol; 2010 Feb; 65(3):527-36. PubMed ID: 19578850
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
Song H; Han B; Park CK; Kim JH; Jeon JY; Kim IG; Kim HJ; Jung JY; Kim JH; Kwon JH; Jang G; Kim HY; Kim HS; Choi DR; Zang DY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):845-52. PubMed ID: 23978987
[TBL] [Abstract][Full Text] [Related]
4. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Ioka T; Komatsu Y; Mizuno N; Tsuji A; Ohkawa S; Tanaka M; Iguchi H; Ishiguro A; Kitano M; Satoh T; Yamaguchi T; Takeda K; Kida M; Eguchi K; Ito T; Munakata M; Itoi T; Furuse J; Hamada C; Sakata Y
Br J Cancer; 2017 Feb; 116(4):464-471. PubMed ID: 28081543
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Ozaka M; Matsumura Y; Ishii H; Omuro Y; Itoi T; Mouri H; Hanada K; Kimura Y; Maetani I; Okabe Y; Tani M; Ikeda T; Hijioka S; Watanabe R; Ohoka S; Hirose Y; Suyama M; Egawa N; Sofuni A; Ikari T; Nakajima T
Cancer Chemother Pharmacol; 2012 May; 69(5):1197-204. PubMed ID: 22249272
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Morizane C; Okusaka T; Furuse J; Ishii H; Ueno H; Ikeda M; Nakachi K; Najima M; Ogura T; Suzuki E
Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
[TBL] [Abstract][Full Text] [Related]
7. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Kim HS; Kim HY; Zang DY; Oh HS; Jeon JY; Cho JW; Park CK; Kim JH; Kim MJ; Ha HI; Kim JH; Han B; Song H; Kwon JH; Choi DR; Jung JY
Cancer Chemother Pharmacol; 2015 Apr; 75(4):711-8. PubMed ID: 25630414
[TBL] [Abstract][Full Text] [Related]
9. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
Ohkawa S; Okusaka T; Isayama H; Fukutomi A; Yamaguchi K; Ikeda M; Funakoshi A; Nagase M; Hamamoto Y; Nakamori S; Tsuchiya Y; Baba H; Ishii H; Omuro Y; Sho M; Matsumoto S; Yamada N; Yanagimoto H; Unno M; Ichikawa Y; Takahashi S; Watanabe G; Wakabayashi G; Egawa N; Tsuda M; Hosotani R; Hamada C; Hyodo I
Br J Cancer; 2015 Apr; 112(9):1428-34. PubMed ID: 25880004
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Ueno H; Okusaka T; Ikeda M; Ishiguro Y; Morizane C; Matsubara J; Furuse J; Ishii H; Nagase M; Nakachi K
Oncology; 2005; 69(5):421-7. PubMed ID: 16319514
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
Saito K; Isayama H; Nakai Y; Takahara N; Ishigaki K; Takeda T; Hakuta R; Saito T; Uchino R; Kishikawa T; Hamada T; Mizuno S; Sasaki T; Kogure H; Matsubara S; Yamamoto N; Ijichi H; Tateishi K; Tada M; Koike K
Invest New Drugs; 2019 Apr; 37(2):338-344. PubMed ID: 30411217
[TBL] [Abstract][Full Text] [Related]
13. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
Kim MK; Lee KH; Jang BI; Kim TN; Eun JR; Bae SH; Ryoo HM; Lee SA; Hyun MS
Jpn J Clin Oncol; 2009 Jan; 39(1):49-53. PubMed ID: 19060295
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Hamada C; Okusaka T; Ikari T; Isayama H; Furuse J; Ishii H; Nakai Y; Imai S; Okamura S
Br J Cancer; 2017 Jun; 116(12):1544-1550. PubMed ID: 28472821
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer.
Cheng YJ; Meng CT; Shao YJ; Li NN; Zhou N; Yan XY; Gao X; Zhou JF; Bai CM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):562-567. PubMed ID: 28877836
[TBL] [Abstract][Full Text] [Related]
16. A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
Kanai M; Yoshimura K; Tsumura T; Asada M; Suzuki C; Niimi M; Matsumoto S; Nishimura T; Nitta T; Yasuchika K; Taura K; Mori Y; Hamada A; Inoue N; Tada S; Yanagihara K; Yazumi S; Osaki Y; Chiba T; Ikai I; Fukushima M; Uemoto S; Hatano E
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1429-34. PubMed ID: 20811895
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.
Lee GW; Kim HJ; Ju JH; Kim SH; Kim HG; Kim TH; Kim HJ; Jeong CY; Kang JH
Cancer Chemother Pharmacol; 2009 Sep; 64(4):707-13. PubMed ID: 19151975
[TBL] [Abstract][Full Text] [Related]
18. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Okusaka T; Miyakawa H; Fujii H; Nakamori S; Satoh T; Hamamoto Y; Ito T; Maguchi H; Matsumoto S; Ueno H; Ioka T; Boku N; Egawa S; Hatori T; Furuse J; Mizumoto K; Ohkawa S; Yamaguchi T; Yamao K; Funakoshi A; Chen JS; Cheng AL; Sato A; Ohashi Y; Tanaka M;
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1053-1059. PubMed ID: 28210843
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
Nakachi K; Furuse J; Kinoshita T; Kawashima M; Ishii H; Ikeda M; Mitsunaga S; Shimizu S
Cancer Chemother Pharmacol; 2010 Aug; 66(3):527-34. PubMed ID: 19967537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
